Last reviewed · How we verify
NCT06567028
OSPM-Enhanced AI Model to Identify Premalignant and Malignant Ocular Surface Tumors
trial testing OSPM-Enhanced AI Model in Performance of the Model in 150 participants. Completed in 1 November 2024.
1 October 2024
Quick facts
| Lead sponsor | Ningbo Eye Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 June 2024 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- OSPM-Enhanced AI Model
Conditions studied
- Performance of the Model — all drugs for Performance of the Model →
Sponsor
Ningbo Eye Hospital
Who can join
Adults 1 to 100, any sex, with Performance of the Model. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An OSPM-enhanced deep learning model has been developed for identifying premalignant and malignant tumors using data retrospectively collected from the Ningbo Eye Hospital, Jiangdong Eye Hospital, and the Eye Hospital of Wenzhou Medical University. To further substantiate the model's effectiveness, we intend to evaluate it prospectively at Ningbo Eye Hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06567028
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ningbo Eye Hospital trials
Trials by the same sponsor.
- NCT07129889 — Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine · NA · not yet recruiting
- NCT05836194 — Evaluation of Diabetic Retinopathy Using Ultra-Widefield Fundus Images Compared With Two-Field Fundus Images · completed
- NCT05538793 — Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06567028 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ningbo Eye Hospital
- Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567028.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing